PubMed Health⌕ Search

Biomedical subjects

M Shozu

Publications and source records attributed to M Shozu.

22 records · Page 2Linked to original sources

Genetic studies to characterize the origin of the mutation in placental aromatase deficiency.

Placental aromatase deficiency has recently been shown to be due to expression of RNA transcripts encoding abnormal aromatase molecules with 29 extra amino acids. To establish whether this aromatase deficiency is a hereditary or sporadic disease, we examined the genetic defect of the aromatase gene in the family of a patient. Direct sequencing of fragments of the aromatase gene prepared by PCR revealed that the splicing donor sequence (GT) of intron 6 in controls was mutated to GC in the patient, whereas the parents showed signals of both GT and GC. Subcloning of PCR products of the parents gave two different types of clones with GT and GC sequences in this site. Furthermore, for diagnosis of this deficiency, competitive-oligo-nucleotide-priming PCR of genomic DNA was performed in the presence of both normal and mutational oligonucleotide primers labeled with two kinds of fluorescent dyes, and the products were separated by agarose gel electrophoresis and were detected fluorometrically in the gel. Genomic DNA of the patient gave a PCR product primed only by the mutational primer, whereas that of controls gave a product primed only by the normal primer. The PCR products of the parents were primed by both primers. The results obtained by this fluorometric method were also confirmed by differential hybridizations with specific oligonucleotide probes. Thus these findings indicate that this deficiency is an autosomal hereditary disease and that the patient is a homozygote, while the parents are heterozygotes, for this mutation.

Aromatase↗

Treatment of an antenatally diagnosed fetal ovarian cyst by needle aspiration during the neonatal period.

An ultrasound scan revealed an ovarian cyst in the fetal lower abdomen at 29 weeks of gestation. Repeated examinations demonstrated that the cyst increased in size to 6.5 cm x 6.1 cm x 5.0 cm at 33 weeks of gestation, and the cyst showed no complications between 29 weeks of gestation and early infancy. The female infant was vaginally delivered at 41 weeks of gestation without any complications. Transabdominal needle aspiration of the cyst fluid was performed on the 14th day after birth. The concentrations of estrone, estradiol, estriol, and progesterone in the cyst fluid were almost the same as those in the infant's serum, while the concentration of pregnenolone was six times that in the infant's serum. Cytology of the cyst fluid was negative. The cyst thus seems to have been a non-functioning simple cyst of ovarian origin. Follow-up until the baby was one year old showed no recurrence of the cyst.

Adult↗

A new cause of female pseudohermaphroditism: placental aromatase deficiency.

A description is presented of the first documented case of placental aromatase deficiency. The deficiency caused maternal virilization during pregnancy and pseudohermaphroditism of the female fetus. A 24-yr-old primigravida showed progressive virilization during the third trimester. Urinary excretion of estrogen was less than 14 mumol/day between 35-38 weeks of pregnancy, although nonstress tests showed reactive patterns and serum levels of human placental lactogen were above 460 nmol/L. Maternal serum levels of estrogens were low, and those of androgens were high in the third trimester. A dehydroepiandrosterone sulfate loading test induced a marked increase in maternal serum levels of androgens, whereas no such increase was observed in estrogens. The woman delivered vaginally a live full-term infant who exhibited female pseudohermaphroditism. Cord serum levels of estrogens were extremely low, while those of androgens were high. The aromatase activity of the placenta, determined by the conversion of [7-3H]androstenedione to 17 beta-[7-3H]estradiol and [7-3H]estrone, were less than 0.03 fmol/microgram protein.min (control, 9.6 +/- 2.2 fmol/microgram protein.min). The sulfatase activity of the placenta was 0.63 pmol/microgram protein.min compared to 0.46 +/- 0.16 pmol/microgram protein.min in controls. The rate of aromatization by normal control placentas was the same as that obtained during coincubation of samples of normal placentas and that of the patient. Thus, the presence of aromatase inhibitor in the patient's placenta was excluded.

Adult↗

[Fundamental and clinical study of T-1982 (cefbuperazone) in the field of obstetrics and gynecology].

Laboratory and clinical investigation of T-1982 (cefbuperazone) in the field of obstetrics and gynecology were carried out and the following results were obtained. The peak concentrations of 18.1-36.0 micrograms/ml were noted in pelvic cavity fluid at 1-3 hours after intravenous injection or drip infusion of 1 g of T-1982 in 3 cases after total hysterectomy for diffuse uterine cancer, then the concentrations decreased very slowly and were over 10 micrograms/ml at 6 hours after administration. Transfer rate of the drug into pelvic cavity fluid was 33-66% of the serum concentrations. In clinical trial, a total of 5 cases including 4 cases of external genital infections and 1 case of pelvic infection were treated with T-1982, and the results were evaluated as good in 3 cases, poor in 1 case and unknown in 1 case. Side effects were observed in 1 case who showed slight increase of GOT and GPT.

Abscess↗